Clinical trial
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated…
NCT01696084 · Jazz Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT01696084 |
|---|---|
| Title | Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia |
| Official title | Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age With Untreated High Risk (Secondary) AML |
| Acronym | 301 |
| Lead sponsor | Jazz Pharmaceuticals, Industry |
| Collaborators | The Leukemia and Lymphoma Society |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | High Risk Acute Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | CPX-351, 7+3 (cytarabine and daunorubicin) |
| Enrollment | 309 |
| Start date | Dec 13, 2012 |
| Primary completion | Dec 31, 2015 |
| Completion | Dec 31, 2015 |
| First posted | Sep 28, 2012 |
| Last update posted | Aug 10, 2020 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: